Clinical trial
Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day…
NCT03694353 · BioMarin Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT03694353 |
|---|---|
| Title | Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU |
| Official title | An Open-label Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Injections of Pegvaliase (> 40 mg/Day Dose) in Adults With Phenylketonuria |
| Lead sponsor | BioMarin Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Phenylketonuria (PKU) |
| Intervention type | Drug |
| Interventions | Pegvaliase |
| Enrollment | 37 |
| Start date | Sep 13, 2018 |
| Primary completion | Jan 13, 2021 |
| Completion | Jan 13, 2021 |
| First posted | Oct 3, 2018 |
| Last update posted | Feb 17, 2022 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: